CN116462674A - 吗啉基吡啶酮化合物 - Google Patents

吗啉基吡啶酮化合物 Download PDF

Info

Publication number
CN116462674A
CN116462674A CN202310448740.0A CN202310448740A CN116462674A CN 116462674 A CN116462674 A CN 116462674A CN 202310448740 A CN202310448740 A CN 202310448740A CN 116462674 A CN116462674 A CN 116462674A
Authority
CN
China
Prior art keywords
trifluoromethyl
alkyl
methyl
piperazin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310448740.0A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·林德斯特罗姆
里卡德·福斯布罗姆
詹妮·维克兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sprint Bioscience AB
Original Assignee
Sprint Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience AB filed Critical Sprint Bioscience AB
Publication of CN116462674A publication Critical patent/CN116462674A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310448740.0A 2017-08-23 2018-08-23 吗啉基吡啶酮化合物 Pending CN116462674A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS
CN201880060742.XA CN111108102B (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880060742.XA Division CN111108102B (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Publications (1)

Publication Number Publication Date
CN116462674A true CN116462674A (zh) 2023-07-21

Family

ID=59686888

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310448740.0A Pending CN116462674A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN201880060742.XA Active CN111108102B (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN202310448700.6A Pending CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201880060742.XA Active CN111108102B (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物
CN202310448700.6A Pending CN116444510A (zh) 2017-08-23 2018-08-23 吗啉基吡啶酮化合物

Country Status (20)

Country Link
US (2) US11560374B2 (enExample)
EP (2) EP3672962B1 (enExample)
JP (2) JP7199736B2 (enExample)
KR (1) KR102732013B1 (enExample)
CN (3) CN116462674A (enExample)
AU (2) AU2018320419B2 (enExample)
CY (1) CY1125117T1 (enExample)
DK (1) DK3672962T3 (enExample)
ES (1) ES2910157T3 (enExample)
HR (1) HRP20220497T1 (enExample)
HU (1) HUE058661T2 (enExample)
IL (3) IL302077A (enExample)
LT (1) LT3672962T (enExample)
PL (1) PL3672962T3 (enExample)
PT (1) PT3672962T (enExample)
RS (1) RS63109B1 (enExample)
SI (1) SI3672962T1 (enExample)
SM (1) SMT202200169T1 (enExample)
TW (2) TW202348601A (enExample)
WO (1) WO2019038390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414955B2 (en) 2020-11-25 2025-09-16 Deciphera Pharmaceuticals, Llc Anti-viral activity of VPS34 inhibitors
CN117241800A (zh) * 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
JP2023550641A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ，エルエルシー ウイルス感染症の治療に使用するためのｖｓｐ３４阻害剤としてのモルホリノ誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
FR2969612A1 (fr) * 2010-12-23 2012-06-29 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
US8685993B2 (en) 2010-12-21 2014-04-01 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
HUE024504T2 (en) * 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) * 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MY182908A (en) 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
SI3416957T1 (sl) * 2016-02-19 2020-11-30 Sprint Bioscience Ab Spojine 6-heterociklil-4-morfolin-4-ilpiridin-2-ona, uporabne za zdravljenje raka in diabetesa
AU2017219846B2 (en) * 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
FR2969612A1 (fr) * 2010-12-23 2012-06-29 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩

Also Published As

Publication number Publication date
KR102732013B1 (ko) 2024-11-18
IL292489B1 (en) 2023-05-01
EP3672962B1 (en) 2022-01-26
CN111108102B (zh) 2023-04-28
EP4056569A1 (en) 2022-09-14
TW202348601A (zh) 2023-12-16
SI3672962T1 (sl) 2022-06-30
IL272815A (en) 2020-04-30
PT3672962T (pt) 2022-04-12
RU2020110506A (ru) 2021-09-23
US20200361922A1 (en) 2020-11-19
WO2019038390A1 (en) 2019-02-28
US20230234949A1 (en) 2023-07-27
SMT202200169T1 (it) 2022-05-12
CY1125117T1 (el) 2024-12-13
JP7199736B2 (ja) 2023-01-06
JP2020531485A (ja) 2020-11-05
EP3672962A1 (en) 2020-07-01
HUE058661T2 (hu) 2022-09-28
CN111108102A (zh) 2020-05-05
CA3073142A1 (en) 2019-02-28
CN116444510A (zh) 2023-07-18
US11560374B2 (en) 2023-01-24
ES2910157T3 (es) 2022-05-11
IL292489A (en) 2022-06-01
LT3672962T (lt) 2022-05-10
IL302077A (en) 2023-06-01
IL272815B (en) 2022-06-01
JP2023021268A (ja) 2023-02-10
RU2020110506A3 (enExample) 2022-02-22
KR20200044025A (ko) 2020-04-28
AU2018320419A1 (en) 2020-04-09
AU2023285995A1 (en) 2024-01-25
HRP20220497T1 (hr) 2022-05-27
PL3672962T3 (pl) 2022-05-02
TWI803511B (zh) 2023-06-01
AU2018320419B2 (en) 2023-09-28
RS63109B1 (sr) 2022-04-29
DK3672962T3 (da) 2022-05-02
TW201912161A (zh) 2019-04-01
IL292489B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US11633403B2 (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
CN108884067A (zh) 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
US20230234949A1 (en) Morpholinylpyridone compounds
AU2023258375A1 (en) Pyridylpyridone Compounds
CN116589461A (zh) 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物
CA3073142C (en) Morpholinylpyridone compounds
HK40079060A (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230721